Abstract: A method for controlling protozoa trophozoites and cysts wherein one or more biocides or non-biocidal agents are encapsulated within a micro-capsule or nano-capsule and then introduced into an aqueous system. The micro-capsule or nano-capsule has an exterior composition adapted for digestion by the protozoa. A vesicle for controlling protozoa trophozoites and cysts is also provided.

Abstract: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease inhibitor is useful as an anti-malarial agent acting on Plasmodium species, for example, Plasmodium vivax; and a method of identifying the activity of VX-4, are provided.

Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.

Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.

Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.

Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.

Abstract: A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals.

Abstract: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation.

Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.

Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.

Abstract: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.

Abstract: Compositions comprising the Cryptosporidium sporozoite antigens such as SRK (‘similar to riken’), CP15 and profilin are used in vaccines against the protozoan parasite Cryptosporidim.

Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.

Abstract: The present invention provides isolated polynucleotides, polypeptides, antibodies and/or vaccines for the prevention and/or treatment of malaria caused by Plasmodium falciparum and/or Plasmodium vivax. In particular, the polypeptide fragments are derived from the binding domain of the reticulocyte binding proteins of Plasmodium falciparum and/or Plasmodium vivax. The present invention also provides recombinant vaccines and their use in the prevention and/or treatment of malaria.

Abstract: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.

Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.

Abstract: This invention relates to a conjugate molecule comprising at least one first portion (I) comprising a carrier sequence and at least one second portion (II) comprising at lest one antitumor drug molecule or a protease inhibitor molecule said conjugate molecule comprising D-enantiomeric amino acids in its portion (I). Furthermore, the invention relates to pharmaceutical compositions containing said conjugate molecule as well as to the use of said conjugate molecule for therapeutic treatment. Methods for improving cell permeability or water solubility are disclosed as well.